首页 /研究 /81MO Osimertinib as neoadjuvant therapy in patients with EGFR mutated resectable stage II-IIIB lung adenocarcinoma (NEOS): Updated results
OTHER

81MO Osimertinib as neoadjuvant therapy in patients with EGFR mutated resectable stage II-IIIB lung adenocarcinoma (NEOS): Updated results

Chuhl Joo Lyu, Wentao Fang, Weiqi Jiao, Haitao Ma, J. Wang, S. Xu, Nan Wu, R. Wang, Yongbo Yang

发表年份
2022
引用次数
10

关键词

MedicineOsimertinibNeoadjuvant therapyClinical endpointAdenocarcinomaAdverse effectInternal medicineLung cancerPopulationSurgery

相关论文

查看 OTHER 分类全部论文